Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Eric eTrinquet"'
Autor:
Angélique eLEVOYE, Jurriaan M. eZWIER, Agnieszka eJARACZ-ROS, Laurence eKLIPFEL, Martin eCOTTET, Damien eMAUREL, Sara eBDIOUI, Karl eBALABANIAN, Laurent ePREZEAU, Eric eTRINQUET, Thierry eDURROUX, Françoise eBACHELERIE
Publikováno v:
Frontiers in Endocrinology, Vol 6 (2015)
Although G protein-coupled receptor (GPCR) internalization has long been considered a major aspect of the desensitization process that tunes ligand responsiveness, internalization is also involved in receptor resensitization and signaling, as well as
Externí odkaz:
https://doaj.org/article/1f9abb930d754adcbe12b9d6785ac3d4
Autor:
Mohammed Akli eAyoub, Julien eTrebaux, Julie eVallaghe, Fabienne eCharrier-Savournin, Khaled eAl-Hosaini, Arturo eGonzalez-Moya, Jean-Philippe R Pin, Kevin D G Pfleger, Eric eTrinquet
Publikováno v:
Frontiers in Endocrinology, Vol 5 (2014)
The extracellular signal-regulated kinases (ERKs) are key components of multiple important cell signalling pathways regulating diverse biological responses. This signalling is characterized by phosphorylation cascades leading to ERK1/2 activation and
Externí odkaz:
https://doaj.org/article/583f6d766fab406cb3c3a7bab1991e80
Autor:
Martin eCottet, Orestis eFaklaris, Damien eMaurel, Pauline eScholler, Etienne eDoumazane, Eric eTrinquet, Jean-Philippe R Pin, Thierry eDURROUX
Publikováno v:
Frontiers in Endocrinology, Vol 3 (2012)
The concept of oligomerization of G protein-coupled receptor (GPCR) opens new perspectives regarding physiological function regulation. The capacity of one GPCR to modify its binding and coupling properties by interacting with a second one can be at
Externí odkaz:
https://doaj.org/article/7d60761f71ca4818875a761ab5912fa9
Autor:
Estelle eTallet, Isabelle eFernandez, Chi eZhang, Marion eSalsac, Nathalie eGregor, Mohammed Akli Ayoub, Jean-Philippe ePin, Eric eTrinquet, Vincent eGoffin
Publikováno v:
Frontiers in Endocrinology, Vol 2 (2011)
The prolactin receptor (PRLR) is emerging as a therapeutic target in oncology. Knowledge-based drug design led to the development of a pure PRLR antagonist (Del1-9-G129R-hPRL) that was recently shown to prevent PRL-induced mouse prostate tumorogenesi
Externí odkaz:
https://doaj.org/article/541fd7ca38834ed681e38236319d1d68